An exciting new national study of prostate cancer specific to African Americans has been launched to assess risk factors associated with this group of men and why a higher rate of aggressive disease exists. This study is the first of its kind and researchers hope to uncover targeted treatment strategies for African Americans as a result. Dr. Damali N. Martin introduced this study and provides details on the disparity in prostate cancer burden that exists based on race with data sourced from the National Cancer Institute, where she serves as program director. Dr. Franklin Huang, a principal investigator for the study, covers biological reasons why this group of men is more likely to be diagnosed with the disease. He also outlines the goals of the RESPOND trial and provides details on taking part in the study.